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Abstract
Background: Pneumococcal meningitis is associated with high mortality (~30%) and morbidity.
Up to 50% of survivors are affected by neurological sequelae due to a wide spectrum of brain injury
mainly affecting the cortex and hippocampus. Despite this significant disease burden, the genetic
program that regulates the host response leading to brain damage as a consequence of bacterial
meningitis is largely unknown.
We used an infant rat model of pneumococcal meningitis to assess gene expression profiles in
cortex and hippocampus at 22 and 44 hours after infection and in controls at 22 h after mock-
infection with saline. To analyze the biological significance of the data generated by Affymetrix DNA
microarrays, a bioinformatics pipeline was used combining (i) a literature-profiling algorithm to
cluster genes based on the vocabulary of abstracts indexed in MEDLINE (NCBI) and (ii) the self-
organizing map (SOM), a clustering technique based on covariance in gene expression kinetics.
Results: Among 598 genes differentially regulated (change factor ≥ 1.5; p ≤ 0.05), 77% were
automatically assigned to one of 11 functional groups with 94% accuracy. SOM disclosed six
patterns of expression kinetics. Genes associated with growth control/neuroplasticity, signal
transduction, cell death/survival, cytoskeleton, and immunity were generally upregulated. In
contrast, genes related to neurotransmission and lipid metabolism were transiently downregulated
on the whole. The majority of the genes associated with ionic homeostasis, neurotransmission,
signal transduction and lipid metabolism were differentially regulated specifically in the
hippocampus. Of the cell death/survival genes found to be continuously upregulated only in
hippocampus, the majority are pro-apoptotic, while those continuously upregulated only in cortex
are anti-apoptotic.
Conclusion: Temporal and spatial analysis of gene expression in experimental pneumococcal
meningitis identified potential targets for therapy.
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Background
Bacterial meningitis (BM) is associated with high mortal-
ity (~30%) and morbidity [1,2]. Up to 50% of BM survi-
vors are affected by neurological sequelae that are due to
a wide spectrum of brain injury including neuronal necro-
sis in the cortex (CX) and apoptotic neuronal death in the
hippocampus (HC) [3-5]. Despite this significant disease
burden, the genetic program that regulates the mecha-
nisms leading to brain damage as a consequence of BM is
largely unknown. High-throughput methods, e.g. DNA
microarrays, can provide a comprehensive picture of the
genes underlying the host responses to BM. This knowl-
edge is a prerequisite for understanding the pathogenesis
of brain damage and can drive the development of new
therapeutic modalities for BM.
The evaluation of the functional significance of large
groups of genes constitutes the real challenge for microar-
ray users. Clustering genes according to their expression
patterns may reveal only a partial picture of the biological
implications of the data. To overcome this problem,
methods that extract knowledge from the scientific litera-
ture by gene-name co-citation frequencies [6,7] or by rec-
ognizing patterns of word occurrences [8] have been used.
More recently, a technique has been developed to cluster
genes automatically on the basis of the frequencies of
words present in abstracts indexed in the National Center
for Biotechnology Information (NCBI) PubMed
MEDLINE database [9].
The aim of this study was to identify genes and sets of
genes implicated in the pathophysiological mechanisms
leading to the neuronal damage observed in BM. We used
an infant rat model of pneumococcal meningitis and
DNA microarray technology to assess gene expression
profiles in the brain regions known to be preferentially
damaged, i.e. CX and HC in mock-infected controls and
during the early (22 h) and late (44 h) phases of acute BM.
To analyze the data, we implemented a bioinformatics
pipeline for gene clustering combining literature profiling
[9] and co-variance analysis of expression kinetics [9,10].
Results
Animal model
Eighteen hours after infection, all infected animals (n =
10) had meningitis as evidenced by the clinical status and
positive bacterial titers in the cerebrospinal fluid (CSF)
(log10 7.3 ± 0.6 cfu/ml).
Microarrays
In total, 598 Affymetrix probe sets showing a change fac-
tor ≥ 1.5 (p ≤ 0.05) were selected. These represent 458
unique named genes and 67 expressed sequence tags
(ESTs)/unnamed genes that were differentially regulated
in the CX and/or in the HC when at least two of the
defined conditions were compared (i.e.: CX 22 h vs. CX
mock-infected, OR CX 44 h vs. CX mock-infected, OR CX
44 h vs. CX 22 h, OR HC 22 h vs. mock-infected, OR HC
44 h vs. mock-infected, OR HC 44 h vs HC 22 h).
Literature profiling
Between 1 and 100 abstracts were found in MEDLINE for
454 out of the 458 named genes represented in the Gene-
Chip® Rat Genome U34A by 598 probe-sets (total 32973
abstracts). The term-by-gene matrix generated comprised
444 genes and 1074 valid terms (ten genes had no charac-
teristic term passing the filters). Twenty-eight clusters of
genes forming nodes in the clustergram with a correlation
varying from 0.114 to 0.948 were extracted and, in 25
cases, two or more clusters were manually merged to com-
pose a larger group of genes with related functions. Eleven
functional groups that may play a role in the host
response to BM were identified. Genes not related to any
pathophysiological mechanism known to be relevant in
BM were categorized as "Miscellaneous". Seventy-seven
per cent (462/598) of the probe sets were automatically
assigned to one of the 11 functional groups (or to the
ESTs/unnamed genes, or the miscellaneous groups) with
94% accuracy (manually checked). Twenty-nine genes
were found to fit better in a functional group different
from the one to which they were automatically assigned.
The remaining 136 probe-sets that were not grouped by
the automatic approach were manually transferred to one
of the 13 groups (Figure 1).
Self-organizing map
The SOMs algorithm disclosed 24 clusters of probe-sets
representing 6 expression kinetic patterns (Figure 2):
1) Transient upregulation in early acute meningitis (29.1
%);
2) Continuous upregulation in early and late acute men-
ingitis (29.4 %);
3) Transient downregulation in early acute meningitis
(27.8 %);
4) Continuous downregulation in early and late acute
meningitis (8.9 %);
5) Transient upregulation in early acute meningitis in the
CX, and continuous upregulation in early and late acute
meningitis in the HC (2.8 %);
6) Transient downregulation in early acute meningitis in
the CX and continuous upregulation in early and late
acute meningitis in the HC (2.0 %).BMC Biology 2006, 4:15 http://www.biomedcentral.com/1741-7007/4/15
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Overview of differential gene regulation
Overall, genes associated with growth control/neuroplas-
ticity, signal transduction, cell death/survival, cytoskele-
ton, innate and adaptive immunity were upregulated. In
contrast, most genes related to neurotransmission and
lipid metabolism were downregulated. The majority of
the genes associated with ionic homeostasis, neurotrans-
mission, signal transduction and lipid metabolism were
differentially regulated only in the HC. The other func-
tional groups identified were: redox homeostasis and
extracellular matrix/vasculature (Figures 1 and 2). Table 1
presents a list of 102 probe sets and their respective
expression values in the CX and in the HC at the three
time-points. They represent the 83 genes discussed below.
These genes were selected because they were continuously
up- or down-regulated during the early and late phases of
acute BM, thus representing potential targets for therapeu-
tic intervention at the time of onset of pathophysiological
processes leading to brain injury. Eighty percent of these
genes (66/83) have not previously been reported in BM.
Discussion
Functional analysis
The pathogenesis of brain damage in BM arises from the
interplay of bacteria and the host inflammatory response.
It is generally accepted that the release of bacterial prod-
ucts (such as peptidoglycan and lipoteichoic acid,
lipopolysaccharide, pneumolysin and bacterial DNA)
into the CSF triggers the inflammatory response in the
subarachnoid space by inducing the production and
release of inflammatory cytokines, chemokines and lipid
inflammatory mediators. These bacterial products also
upregulate adhesion molecules in brain vascular endothe-
lial cells and promote the recruitment of granulocytes into
the CSF leading to the pronounced pleocytosis character-
istic of BM. Granulocytic inflammation has a central role
in the complex central nervous system (CNS) alterations
associated with BM [11-14]. The pathophysiology of BM
can be summarized as a sequence of sometimes overlap-
ping processes that culminate in neuronal death of either
the necrotic or apoptotic type in the CX or HC, respec-
tively (Figure 3).
Signaling cascade
It is difficult to assign biological functions to individual
signal transduction molecules or transcription factors in
the context of BM since they are likely to play a role in
modulating different activities in many cell types within
the infected brain. Our intention here is to highlight
hypotheses arising from our results that are supported by
literature data. Further investigations are required to test
these hypotheses.
One of the first steps in the host immune response to BM
is the activation of Toll like receptor 2 by binding of pep-
tidoglycan (and/or lipoteichoic acid) to the CD14 mono-
cyte membrane receptor (Table 1, #01, #02) [15]. Soluble
CD14 (sCD14) can also act as an inflammatory co-ligand
in vivo. In a murine model of pneumococcal meningitis
increased CSF concentrations of sCD14 correlates with
CD14 transcriptional upregulation mainly in intrathecal
leukocytes [16]. In the infant rat model of pneumococcal
meningitis, the two distinct expression kinetics of CD14
observed in the CX and in the HC suggest that parenchy-
mal cells, most likely astrocytes and microglia, also con-
tribute to the inflammatory cascade by increasing CD14
expression. This idea is further supported by our findings
that CD14 and TNF-alpha (Table 1, #20) were both con-
tinuously upregulated only in the HC in the early and late
Distribution of probe-sets in automatically disclosed func- tional groups by literature-profiling Figure 1
Distribution of probe-sets in automatically disclosed 
functional groups by literature-profiling. (a) Cluster-
gram showing 444 named genes clustered according to the 
similarities between the patterns of occurrence of 1074 
terms in their abstracts; detail showing one cluster of genes 
related to redox homeostasis. (b) The number of probe-sets 
in each functional group.BMC Biology 2006, 4:15 http://www.biomedcentral.com/1741-7007/4/15
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Gene clustering by self-organizing maps (SOM) (a, b) and literature-profiling (b) Figure 2
Gene clustering by self-organizing maps (SOM) (a, b) and literature-profiling (b). (a) Genes clustered according to 
their expression dynamics (SOM): twenty-four clusters were disclosed by the SOMs algorithm, which were grouped into 6 pat-
terns, i.e.: (1) genes transiently upregulated in the acute phase (yellowish); (2) genes continuously upregulated in the acute and 
the late phase (reddish); (3) genes transiently downregulated in the acute phase (bluish); (4) genes continuously downregulated 
in the acute and the late phase (greenish); (5) genes transiently upregulated in CX and continuously upregulated in HC (black); 
(6) genes transiently downregulated in CX and continuously upregulated in HC (brown). Patterns 1, 2 and 3 are subdivided 
into "mega-clusters" comprising clusters of genes differentially regulated only in CX, or only in HC, or in both tissues concom-
itantly. Pattern 4 contained two clusters, one with genes continuously downregulated only in CX, the other with genes contin-
uously downregulated only in HC. In each cluster diagram, the three points on the left side represent the average gene 
expression levels in the CX in mock-infected animals, and in infected animals in the acute and the late phase, respectively. The 
three points on the right side refer to gene expression in the HC at these time points. cn is the identification of each cluster, 
and the following values correspond to the number of probe-sets comprising the cluster. Clusters c4, c5, c6, c7, c10, c11, c14, 
c15, c18 and c21 contain 227 probe-sets representing genes with a similar gene expression pattern in CX and HC; Clusters c8, 
c9, c12, c19, c22 and c23 contain 157 probe-sets representing genes differentially regulated only in the CX; Clusters c0, c1, c2, 
c3, c13, c16 and c17 contain 214 probe-sets representing genes differentially regulated only in the HC. (b) Combined clustering 
obtained with self-organizing maps and literature-profiling: Cold colors (bluish and greenish) represent genes that were down-
regulated, and warm colors (yellowish and reddish) represent genes that were upregulated. The corresponding clusters dis-
closed by the SOM algorithm are indicated in the box, following the same color schema of Figure 3(a). Detached pieces in the 
pies represent genes differentially regulated only in the HC.BMC Biology 2006, 4:15 http://www.biomedcentral.com/1741-7007/4/15
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phases of acute BM. TNF-alpha is known to activate the
expression of CD14 [17].
Once triggered by the activation of Toll like receptor 2, the
inflammatory cascade characteristic of BM is initiated by
cytokines. The signalling events induced by cytokines
include activation of an appropriate G coupled protein
complex and stimulation of phospholipases the products
of which activate a subset of protein kinase C leading to
the phosphorylation of other signalling proteins.
Our data suggest a role for the G protein-coupled receptor
VTR 15–20 (Table 1, #03) in the late events of the acute
inflammatory reaction in the HC that leads to neuron
death by apoptosis. The VTR 15–20 is well known to mod-
ulate neuro-immune function, and its expression in brain
and spleen is regulated by immunological challenge [18].
The continuous upregulation of phospholipase A2 (Table
1, #06) from early to late acute BM might prolong the
inflammation in the HC since this enzyme is required for
the production of protaglandins, leukotrienes and plate-
let-activating factor by inflammatory cells in response to
stimuli [19,20].
Phospholipase D1 (Table 1, #07) hydrolyzes phosphati-
dylcholine to generate phosphatidic acid, and choline, an
important mechanism of cell signal transduction
(reviewed in [21]). Our data suggest this to be mainly a
component of the cortical signalling cascade in response
to BM.
Activation of protein kinase C-delta (Table 1, #04, #05) is
crucial for neutrophil apoptosis [22] ensuring the resolu-
tion of the inflammatory response. This is possibly part of
an intrinsic mechanism to limit the extent of the inflam-
mation in the CX in pneumococcal meningitis. Interest-
ingly, we found no evidence of the activation of this
mechanism in the HC.
Lipocortin III (Table 1, #95), or annexin III, an enzyme of
inositol phosphate metabolism, can down-modulate the
inflammation through inhibition of phospholipase A2
(see above) [23]. The simultaneous upregulation of
lipocortin III and phospholipase A2 in the HC during the
early and late acute BM suggests that these two molecules
might interact in a feedback loop to modulate the local
inflammatory response.
The phosphatidylinositol 3' kinase (PI3K, the p55 subunit
of which was transiently downregulated only in the HC in
the present study – data not shown) pathway plays a cen-
tral role in regulating numerous biological processes
known to be relevant to the pathophysiology of BM,
including cell adhesion, migration, activation and sur-
vival [24,25]. However, the involvement of PI3K and its
modulators in the pathophysiology of BM has not yet
been proved. Another component of the inositol signal-
ling system, inositol polyphosphate 5' phosphatase
(SHIP) (Table 1, #10), can negatively modulate the PI3K
signalling pathway by hydrolyzing the second messenger
PI-3,4,5-trisphosphate generated by PI3K [24]. The upreg-
ulation of SHIP might inhibit the PI3K signalling path-
way, ultimately triggering the apoptotic program in HC
neurons.
It has recently been reported that inhibiting tyrphostin AG
126-sensitive tyrosine-protein kinase pathways improves
the outcome in experimental pneumococcal meningitis
[26]. According to our data, Lyn and p56-hck (Table 1,
#11–#13) are the only tyrosine-protein kinases to be
highly upregulated during the early and late phases of
acute BM, making them potential targets for inhibition by
tryphostin AG126. However, the sensitivity of Lyn and
p56-hck to inhibition by AG126 has not been proven to
date. Nevertheless, Lyn belongs to the Src tyrosine-protein
kinase family that is involved in the CD36-dependent sig-
nalling cascade initiated by beta-amyloid in the Alzhe-
imer's brain. Target disruption of Src kinases downstream
of CD36 inhibits macrophage inflammatory responses to
beta-amyloid, including production of reactive oxygen
species (ROS) and chemokines, and results in decreased
recruitment of microglia to sites of amyloid deposition in
vivo [27].
Bruton's tyrosine kinase (Btk) (Table 1, #14) is a key reg-
ulator of LPS-induced TNF-alpha production. Over-
expression of Btk results in stabilization of TNF-alpha
mRNA [28]. Interestingly, Btk and TNF-alpha (Table 1,
#20) presented opposite transcriptional kinetics in the
HC, i.e. while TNF-alpha mRNA levels progressively
increased in the course of the disease, Btk mRNA levels
decreased.
Schematic representation of the pathophysiological events  during acute and late meningitis Figure 3
Schematic representation of the pathophysiological 
events during acute and late meningitis. Functional 
groups listed in Table 1 are marked with a bold lined box.BMC Biology 2006, 4:15 http://www.biomedcentral.com/1741-7007/4/15
Page 6 of 18
(page number not for citation purposes)
Table 1: Probe-sets representing 83 genes, their expression levels in the CX and in the HC at three time-points, organized according 
to their functional groups and SOMs. In bold are genes previously known to play a role in the pathophysiology of BM. (-) = Avg Diff 
change factor ≥ 1.5, and/or p > 0.05 for all pairwise comparisons.
# AFFY ID REFSEQ 
ID
GENE DESCR CX
mock-
infecte
d
CX
early
acute
phase
CX
Late
acute
phase
HC
mock-
infecte
d
HC
early
acute
phase
HC late
acute
phase
SOM
Signal transduction
01 AF0879
43_s_at
NM_021
744.1
Cd14 monocyte 
differentiation antigen 
cd14 precursor 
73.6 869.4 610.7 33.6 805.4 855.8 c7
02 AF0879
44mRN
A_s_at
NM_021
744.1
Cd14 monocyte 
differentiation antigen 
cd14 precursor 
- - - 102.7 298.7 329.1 c2
03 U76206_
at
NM_1335
77.1
Gpr105 probable g protein-
coupled receptor (vtr 
15–20)
- - - 79.0 132.6 199.4 c3
04 M18330_
at
NM_1333
07.1
Prkcd protein kinase c, delta 
type (npkc-delta)
68.2 135.8 259.9 - - - c19
05 M18330_
g_at
NM_1333
07.1
Prkcd protein kinase c, delta 
type (npkc-delta)
137.1 224.4 445.2 - - - c19
06 U38376_
s_at
NM_1335
51.1
Pla2g4a phospholipase a2 - - - 341.1 637.3 992.7 c3
07 AB00077
8_s_at
NM_0309
92.1
Pld1 phospholipase d1 79.9 86.6 222.3 0.0 0.0 0.0 c19
08 U38812_
s_at
XM_2162
33.1
Itpr1 inositol 1,4,5-
triphosphate receptor 
type 1
5.03 14.47 125.6 - - - c19
09 rc_AA85
9981_at
NM_1722
24.1
Impa2 myo-inositol 
monophosphatase 2
13.47 27.81 90.51 - - - c19
10 U55192_
at
NM_0193
11.1
Inpp5d inositol ployphosphate 5' 
phosphatase (ship)
201.68 155.16 430.00 98.29 84.22 358.8 c14
11 rc_AA94
6044_s_a
t
NM_0308
57.1
Lyn lyn tyrosine-protein 
kinase
34.15 84.15 172.62 22.02 68.72 192.35 c15
12 L14782_s
_at
NM_0308
57.1
Lyn lyn tyrosine-protein 
kinase
40.01 124.89 240.08 52.11 102.81 389.1 c15
13 S74141_s
_at
NM_0131
85.1
Hck tyrosine-protein kinase 
hck (p56-hck)
149.61 316.45 483.81 -22.42 409.21 690.65 c11
14 rc_AA89
2404_at
Btk bruton's tyrosine kinase 
(btk)
- - - 134.22 46.21 -33.89 c20
15 M74488c
ds_s_at
NM_0127
27.1
Camk4 calcium/calmodulin-
dependent protein kinase 
type iv catalytic chain 
(CaM kinase-Gr)
- - - 85.79 48.6 33.04 c20
16 U77038_
g_at
NM_0539
08.1
Ptph6 protein-tyrosine 
phosphatase 1c (ptp-1c)
159.7 304.7 851.4 73.8 224.9 901.7 c15
17 U77038_
at
NM_0539
08.1
Ptph6 protein-tyrosine 
phosphatase 1c (ptp-1c)
-55.5 16.4 165.0 -4.6 8.2 226.5 c15
18 L19180_a
t
NM_0191
40.1
Ptprd receptor-linked protein 
tyrosine 
phosphatase(ptp-p1)
- - - 1106.6 524.8 243.7 c20
19 M10072m
RNA_s_a
t
NM_1385
07.1
Ptprc leukocyte common 
antigen variant 4 (cd45)
-22.25 28.57 132.68 -17.53 14.35 167.07 c15
Innate immunity
20 L00981
mRNA#
2_at
NM_012
675.1
Tnf tumor necrosis factor 
precursor (tnf-alpha)
- - - -64.6 87.3 93.3 c2
21 AJ22281
3_s_at
NM_019
165.1
Il18 interleukin-18 
precursor
30.8 133.6 207.2 21.1 80.1 289.7 c11BMC Biology 2006, 4:15 http://www.biomedcentral.com/1741-7007/4/15
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22 U77777
_s_at
NM_019
165.1
Il18 interleukin-18 
precursor
67.3 148.4 292.6 38.9 119.0 321.0 c15
23 rc_AA89
2553_at
NM_0326
12.1
Stat1 signal transducer and 
activator of transcription 
1
-90.9 295.2 654.8 -66.5 234.4 676.0 c11
24 AF0287
84cds#1
_s_at
NM_017
009.1
Gfap glial fibrillary acidic 
protein
534.9 3993.1 3184.2 923.9 4524.2 4733.2 c7
25 U04808_
at
NM_1335
34.1
Rbs11 cx3c chemokine receptor 
1 (CX3CR1)
74.79 61.15 164.92 58.37 39.06 108.2 c14
26 U10894_
s_at
NM_0171
96.1
Aif1 alograft inflammatory 
factor-1 (aif-1)
174.02 223.69 781.79 168.54 210.13 784.71 c14
27 U17919_
s_at
NM_0171
96.1
Aif1 alograft inflammatory 
factor-1 (aif-1)
687.06 805.9 2154.2 620.75 733.07 2182.6
7
c14
28 X71127_
at
NM_0192
62.1
C1qb complement c1q 
subcomponent, b chain 
precursor
1158.3 1939.1 4410.7 981.7 1652.3 4279.6 c15
29 X71127_
g_at
NM_0192
62.1
C1qb complement c1q 
subcomponent, b chain 
precursor
134.4 507.1 1025.3 176.6 418.8 975.5 c15
30 X52477_
at
NM_016
994.1
complement c3 
precursor
-93.1 493.2 751 81.4 367.5 568 c11
31 M29866
_g_at
NM_016
994.1
complement c3 
precursor
-76.3 465.2 953.3 20.8 439.3 993.2 c11
32 U42719
_at
XM_215
318.1
c4 complement 
protein mRNA
8 120.2 255.7 63.7 86.7 320.2 c15
33 rc_AI63
9117_s_
at
XM_215
326.1
alternative-
complement pathway 
C3/C5 convertase
-519.8 818.2 1142.1 -382.7 1188.8 4030.5
1
c10
34 rc_AA9
00582_a
t
NM_012
488.1
A2m alpha-2-macroglobulin 
precursor
- - - 285.4 599.5 846.0 c3
35 M23566
exon_s_
at
NM_012
488.1
A2m alpha-2-macroglobulin 
precursor
-
1469.4
-5.3 527.7 -609.4 307.7 2352.1 c11
Adaptive immunity
36 M31038_
at
NM_0126
45.1
RT1Aw2 class i histocompatibility 
antigen, non-rt1.a alpha-1 
chain precursor
-103.5 24.5 114.8 - - - c19
37 M24324_f
_at
NM_0126
45.1
RT1Aw2 class i histocompatibility 
antigen, non-rt1.a alpha-1 
chain precursor
767.5 2015.0 3287.2 809.0 2211.3 4525.7 c11
38 M31018_f
_at
XM_2280
21.1
rt1 class i 
histocompatibility 
antigen, aa alpha chain 
precursor
401.5 2335.9 5023.4 416.4 2893.1 7012.5 c15
39 M64795_f
_at
XM_2280
21.1
h-2 class i 
histocompatibility 
antigen, d-37 alpha chain 
precursor
-186.5 -8.3 345.6 -133.0 -15.2 584.4 c15
40 L40362_f
_at
XM_2279
84.1
h-2 class i 
histocompatibility 
antigen, d-k alpha chain 
precursor
189.5 1022.8 2404.2 124.3 1025.7 3378.6 c15
41 X13044_
g_at
NM_0130
69.1
Cd74 h-2 class ii 
histocompatibility 
antigen, gamma chain
-58.7 273.0 2479.2 -79.8 335.3 2427.6 c15
42 X13044_
at
NM_0130
69.1
Cd74 h-2 class ii 
histocompatibility 
antigen, gamma chain
3.5 219.0 1232.5 2.2 187.1 1139.5 c15
Table 1: Probe-sets representing 83 genes, their expression levels in the CX and in the HC at three time-points, organized according 
to their functional groups and SOMs. In bold are genes previously known to play a role in the pathophysiology of BM. (-) = Avg Diff 
change factor ≥ 1.5, and/or p > 0.05 for all pairwise comparisons. (Continued)BMC Biology 2006, 4:15 http://www.biomedcentral.com/1741-7007/4/15
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43 X14254c
ds_at
NM_0130
69.1
Cd74 h-2 class ii 
histocompatibility 
antigen, gamma chain
-68.3 14.9 238.6 -39.3 -10.1 230.2 c15
44 X14254c
ds_g_at
NM_0130
69.1
Cd74 h-2 class ii 
histocompatibility 
antigen, gamma chain
-247.3 -84.2 643.7 -200.6 -108.2 572.6 c15
45 X56596_
at
XM_2280
06.1
RT1.B-
BETA(1)
rt1 class ii 
histocompatibility 
antigen, b-1 beta chain 
precursor (rt1.b-beta(1)).
49.9 141.0 400.2 39.7 138.8 408.3 c15
46 X53054_
at
XM_2153
33.1
rt1 class ii 
histocompatibility 
antigen, d-1 beta chain 
precursor.
-54.0 -7.4 77.3 -24.2 -15.9 96.1 c15
Extracellular matrix/vasculature
47 M12112m
RNA#3_s
_at
NM_0074
28.2
Agt angiotensinogen - - - 227.7 75.3 87.6 c20
48 J04035_at XM_2378
69.1
Trela elastin precursor 
(tropoelastin)
- - - 254.9 51.9 -64.5 c20
49 X02601_
at
NM_133
523.1
Mmp3 stromelysin-1 
precursor (MMP3)
- - - 30.5 76.1 67.1 c2
50 rc_AI16
9327_at
NM_053
819.1
Timp1 metalloproteinase 
inhibitor 1 precursor 
(TIMP1)
352.2 1573.0 1312.1 357.2 1475.4 1913.9 c7
51 rc_AI16
9327_g_
at
NM_053
819.1
Timp1 metalloproteinase 
inhibitor 1 precursor 
(TIMP1)
9.8 2099.0 1779.3 50.6 2171.3 3101.5 c7
Cytoskeleton
52 rc_AA85
9305_s_a
t
NM_1731
11.1
tropomyosin 3 60.7 143.4 184.4 - - - c19
53 X62952_
at
NM_0311
40.1
Vim vimentin 1415.3 3269.2 4141.0 1032.8 3165.7 6517.2 c11
54 rc_AA89
2333_at
XM_1473
57.1
Tuba6 tubulin alpha-6 chain. -58.1 1246.0 1762.2 34.0 989.2 2595.5 c11
55 X73524_
at
NM_0225
31.1
Des desmin 113.1 108.6 32.2 - - - c12
56 rc_AA85
2046_s_a
t
XM_2385
47.1
gamma-smooth muscle 
isoactin promoter and 
exon 1
7.6 65.22 82.99 - - - c19
Redox homeostasis
57 U18729
_at
NM_024
160.1
Cyba nadph oxidase light 
chain subunit p22phox
-40.6 20.3 202.5 -109.7 5.4 255.8 c15
58 rc_AI17
2247_at
NM_017
154.1
Xdh xanthine 
dehydrogenase
-33.5 248.0 420.6 9.1 281.3 529.0 c11
59 J02722cd
s_at
NM_0125
80.1
Hmox1 heme oxygenase 1 -3.4 258.0 389.9 -32.4 385.8 1074.1 c11
60 rc_AI179
610_at
NM_0104
42.1
Hmox1 heme oxygenase 94.5 733.2 797.4 96.5 778.6 1995.6 c10
61 S81433_a
t
S81433.1 heme oxygenase-2 -154.9 -95.2 187.4 - - - c19
62 X07365_
s_at
NM_0308
26.2
Gpx1 glutathione peroxidase 1 1243.0 1709.8 3171.5 1286.8 1683.8 4025.0 c15
63 X12367c
ds_s_at
NM_0308
26.2
Gpx1 glutathione peroxidase 1 310.7 359.2 814.5 278.8 314.5 924.1 c14
Table 1: Probe-sets representing 83 genes, their expression levels in the CX and in the HC at three time-points, organized according 
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64 J03752_at NM_1343
49.1
Mgst1 microsomal glutathione s-
transferase 1
40.8 36.5 110.9 43.5 39.2 428.1 c14
65 AF05603
1_at
NM_0215
93.1
Kmo kynurenine 3-hydroxylase 58.4 80.5 153.2 56.2 64.2 209.3 c15
Cell death/survival
66 C07012_f
_at
NM_1390
96.1
Ppicap cyclophilin c - - - 283.5 750.3 1145.2 c3
67 rc_AA8
91591_a
t
NM_031
356.1
Pdcd8 apoptosis-inducing 
factor (Aif)
- - - 49.8 96.7 132.5 c3
68 X76453_
at
NM_0170
60.1
Hrasls3 h-rev 107 - - - 120.1 213.4 405.7 c3
69 rc_AI231
213_g_at
XM_2376
91.1
metastasis suppressor 
homolog (Kai1)
- - - 89.7 142.7 302.4 c3
70 L12138_a
t
NM_0191
79.1
Tyms thymidylate synthase 
(tsase)
8.5 6.8 53.4 - - - c19
71 U89282_
at
NM_0225
91.1
Tep1 telomerase protein 
component 1 (tlp1)
-92.4 -58.0 66.0 - - - c19
72 U14647
_at
NM_012
762.2
Casp1 caspase-1 56.8 282.8 442.9 53.0 253.6 479.3 c11
73 S79676_
s_at
NM_012
762.2
Casp1 caspase-1 - - - 153.5 361.4 508.0 c3
74 J05122_at NM_0125
15.1
Bzrp peripheral-type 
benzodiazepine receptor
116.0 468.5 964.8 121.8 424.7 1241.2 c15
75 J02962_at NM_0318
32.1
Lgals3 galectin-3 23.7 282.9 470.9 10.9 266.4 751.6 c11
76 L21711_s
_at
NM_0129
76.1
Lgals5 galectin-5 175.3 1620.0 2164.8 240.5 1713.2 3658.9 c11
77 U72741_
g_at
NM_0107
08.1
Lgals9 galectin-9 723.4 2339.9 2827.1 605.9 2388.0 4132.9 c11
78 U72741_
at
NM_0107
08.1
Lgals9 galectin-9 90.4 447.0 388.1 74.3 400.3 566.9 c7
79 rc_AI104
781_at
NM_0172
60.1
Alox5ap 5-lipoxygenase activating 
protein (FLAP)
45.53 116.35 176.86 35.42 81.00 131.91 c11
80 AB00019
9_at
NM_1393
29.1
Cca2 cca2 -10.36 18.14 101.83 - - - c19
81 rc_AA99
8164_s_a
t
NM_1719
91.1
Ccnb1 cyclin b1 61.05 38.71 110.33 41.28 45.38 107.2 c14
82 D16308_
at
XM_2162
76.1
cyclin d2 - - - 222.21 34.01 31.73 c20
83 AF03654
8_at
NM_0540
08.1
Rgc32 rgc-32 - - - 116.07 9.22 9.5 c20
Growth control/neuroplasticity
84 A09811c
ds_s_at
NM_0131
22.1
Igfbp2 insulin-like growth factor 
binding protein 2 
precursor
218.1 744.1 1292.1 - - - c19
85 X52498c
ds_at
NM_021
578.1
Tgfb1 transforming growth 
factor beta 1 
precursor 
59.3 199.0 324.5 115.2 106.2 327.1 c15
86 AF0898
25_at
NM_031
815.1
Inhbe activin beta-e chain 146.2 151.4 40.9 - - - c12
87 S79820_a
t
NM_1725
63.1
Hlf hepatic leukemia factor - - - 207.0 88.9 16.3 c20
88 E03082c
ds_s_at
NM_031
073.1
Ntf3 neurotrophin-3 
precursor (nt-3) 
68.6 103.4 11.3 - - - c12
89 X62322_
g_at
NM_0171
13.1
Grn granulins precursor 543.09 1259.5
1
1686.5 544.37 1010.7
5
1952.9
1
c11
Table 1: Probe-sets representing 83 genes, their expression levels in the CX and in the HC at three time-points, organized according 
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90 X06916_
at
NM_0126
18.1
S100a4 nerve growth factor 
induced protein 42a
211.43 616.49 558.56 133.32 566.98 1346.5
2
c10
Neurotransmission
91 AF02075
7_s_at
NM_0536
56.2
P2rx2 p2x purinoreceptor 2 - - - 54.41 28.99 20.25 c20
92 D63665_
at
NM_0571
24.1
P2ry6 p2y purinoreceptor 6 84.30 312.05 447.53 44.77 213.71 493.88 c11
93 D00833_
g_at
NM_0131
33.1
Glra1 glycine receptor alpha-1 
precursor
- - - 57.99 42.25 16.72 c20
Ionic homeostasis
94 U75916_
at
NM_0115
97.1
Tjp2 zonula occludens 2 - - - 236.4 633.7 576.1 c2
Lipid metabolism
95 AA85021
9_at
NM_0128
23.1
Anx3 lipocortin-iii - - - 30.8 61.5 101.9 c3
Miscellaneous
96 M86389c
ds_s_at
NM_0319
70.1
Hspb1 heat shock 27 kda 
protein (hsp27)
-264.3 112.6 72.1 -157.6 75.5 173 c7
97 U13177_
at
NM_0312
37.1
Ube2d3 ubiquitin-conjugating 
enzyme E2D 3
414.3 220.7 87.2 - - - c12
98 D10729_
s_at
NM_0807
67.1
Psmb8 proteasome subunit beta 
type 8 precursor
51.9 216.6 449.7 74.1 246.4 579.4 c15
99 D10757_
at
NM_0127
08.1
Psmb9 proteasome subunit beta 
type 9 precursor
30 35.3 96.6 4 76.4 131.9 c15
100 D10757_
g_at
NM_0127
08.1
Psmb9 proteasome subunit beta 
type 9 precursor
148.7 820.5 1059.9 120 806.5 1644.2 c11
101 D45249_
g_at
NM_0172
64.1
Psme1 proteasome activator 
complex subunit 1
- - - 2145.6 4508.6 7335.3 c3
102 D45250_
s_at
NM_0172
57.1
Psme2 proteasome activator 
complex subunit 2
405.4 988.1 1494.7 439.3 1047.9 1876 c11
Table 1: Probe-sets representing 83 genes, their expression levels in the CX and in the HC at three time-points, organized according 
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In the hippocampus, CaM kinase-Gr (Table 1, #15) is
localized to the processes and nuclei of developing neu-
rons. This enzyme regulates developing neuron's sensitiv-
ity to Ca2+ at different subcellular levels [29]. We have
previously shown that pneumococcal meningitis triggers
the apoptotic cell death cascade preferentially in progeni-
tor cells and immature neurons in the dentate gyrus [30].
The inflammatory response
Increased CSF concentrations of the proinflammatory
cytokines TNF-alpha, IL-1-beta, IL-6, IL-8 and the anti-
inflammatory IL-10 are characteristic for BM [2]. TNF-
alpha, IL-1-beta and IL-6, the major early-response
cytokines, trigger a cascade of inflammatory mediators
including other cytokines, chemokines, arachidonic acid
metabolites, reactive nitrogen and oxygen intermediates
and proteases [5,31].
In the present study, IL-1-beta and IL-6 were transiently
upregulated in the CX and in the HC during the early
phase of acute BM (data not shown); no changes in the
expression of IL-8 and IL-10 were observed at the time
points investigated. Also, no changes in TNF-alpha (Table
1, #20) expression were observed in the CX. TNF-alpha
stimulates the expression of chemokines and adhesion
molecules, which facilitate the passage of leukocytes from
the circulation into the subarachnoid space. In addition,
TNF-alpha augments the expression of major histocom-
patibility complex molecules (Table 1, #36–#46) and thus
facilitates the cytolytic action of T-lymphocytes [2]. These
are typical events of early acute BM and may correlate with
an increase in the CSF levels of TNF-alpha at the very
beginning of the inflammatory reaction, peaking at 12 h
after infection, i.e. before the first assessment in this study
(22 h) [5]. In the HC, however, TNF-alpha mRNA levels
increased continuously in the early and late phases of
acute BM. This is the first report describing increased TNF-
alpha transcriptional activity in the late phase of acute
experimental BM. The role of TNF-alpha in the late phase
of acute BM in the HC is unknown and experimental
approaches to decipher it have yielded disparate results
[5,32,33]. Neurons with typical apoptotic phenotype in
the dentate gyrus are detectable from ~20 h after experi-
mental infection with pneumococci; the maximal number
of apoptotic neurons has been reported at 36 hours after
infection [34].
Increased concentrations of interleukin-1 beta converting
enzyme (caspase-1; Table 1, #72, #73) and interferon-
gamma-inducing factor (IL-18; Table 1 #21, #22) have
previously been described in BM [2,35]. Indeed, caspase-
1 activates IL-18 [36].
Signal transducer and activator of transcription 1 (STAT1;
Table 1, #23) is directly activated by ROS in the brain. It
participates in the regulation of cytokine-signalling and
cellular responses, particularly to interferon-gamma. In
addition, STAT1 is activated and translocated within
ischemic neurons and may contribute to brain injury by
regulating transcription and phosphorylation of proteins
related to apoptosis and cell death [37].
5-lipoxygenase activating protein (FLAP; Table 1, #79)
functions as a facilitator of 5-lipoxygenase (5-LOX) activ-
ity. The enzyme 5-LOX catalyzes the production of leuko-
triene A4 from free arachidonic acid released from
membrane phospholipid by phospholipase A2 (Table 1,
#06) [38]. Besides its role in leukotriene metabolism,
some evidence suggests that FLAP is also an inhibitor of
apoptosis [39].
Blood-brain barrier disruption
The permeability of the blood-brain barrier (BBB)
increases in BM [2] compromising homeostasis in the
neural microenvironment. High levels of alpha-2 mac-
roglobulin in the CSF correlate with BBB damage associ-
ated with BM [40]. Although leakage from plasma into the
CSF may be important, our results suggest that a local up-
regulation of the alpha-2 macroglobulin gene (Table 1,
#34, #35) in the brain parenchyma may also contribute to
its increased levels found in the CSF in BM.
The local production of angiotensinogen (Agt, Table 1,
#47) by astrocytes in the brain parenchyma is required for
maintenance of the BBB [41]. In spite of the downregula-
tion of angiotensin in the HC, its transcriptional rate did
not change in the CX, where, owing to the larger volume,
it might have more dramatic effects on the integrity of the
BBB. Rupture of the BBB is associated with the separation
of intercellular tight junctions by breakdown of occludin
and reorganization of the actin cytoskeleton [42]. In
response, the transcriptional rates of genes encoding cell
junction or cytoskeleton proteins were changed predomi-
nantly towards upregulation (Table 1, #53–#56, #94).
Metalloproteinases (MMPs) are produced as part of the
immune response to bacteria. In addition to their activity
as modulators of inflammation, they also degrade extra-
cellular matrix proteins, increasing the permeability of the
BBB [43] in early BM [44]. We have previously docu-
mented the transcriptional upregulation of MMP-3 (Table
1, #95–#97), -9 and -14 in infant rat brain tissue at 22 h
after experimental pneumococcal meningitis [5,45].
Moreover, higher CSF levels of MMP-9 and TIMP-1 are
associated with poor outcome in children with BM [46].
In the present study, MMP-9 and -14 were transiently
upregulated only in the early phase of acute BM (data not
shown). Interestingly, this is the first report of the upreg-
ulation of MMP-3 and the metalloproteinase inhibitor
TIMP-1 (Table 1, #98, #99) in the late phase of acuteBMC Biology 2006, 4:15 http://www.biomedcentral.com/1741-7007/4/15
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experimental BM. On the protein level, the time course of
TIMP-1 concentration within the cortices of rats with
pneumococcal meningitis was assessed in a recent study
[14]. The concentration of TIMP-1 protein peaked at 24
hours after infection (6.8-fold vs. sham infection) and
subsequently decreased at 36 hours after infection (4.7-
fold vs. sham infection). These findings are in good agree-
ment with the data presented herein, where we found a
4.4-fold increase of TIMP-1 mRNA expression at 22 hours
after infection and a 3.7-fold increase at 44 hours after
infection.  The contribution of MMPs to the pathophysio-
logical events occurring in the late phase of acute BM is
still largely unknown. Treatment with different MMP
inhibitors led to a significant reduction of mortality and
reduced the extent of cortical damage, but only one com-
pound combining the properties of MMP and TACE (TNF-
alpha converting enzyme) inhibitor prevented neurons
from undergoing apoptosis in the HC and preserved
learning performance in survivors of experimental BM [5].
In the light of the above-mentioned data it is conceivable
that specific MMPs might be involved in the late patho-
physiological events leading to apoptosis in the hippoc-
ampal neurons in BM. Thus, MMPs and TIMPs may
represent candidate targets for pharmacological modula-
tion aimed at improving the outcome of BM.
Redox homeostasis
Reactive oxygen species (ROS) and nitric oxide (NO) have
been implicated as key mediators in the pathophysiology
of BM [47], contributing, among other effects, to disrup-
tion of the BBB [2].
The multi-subunit enzyme complex NADPH oxidase
(Table 1, #57) catalyzes the reduction of O2 into the
superoxide anion O2
￿- in phagocytic cells as part of the
host defence against invading microorganisms. Superox-
ide generated by NADPH oxidase(s) has been shown to be
important for establishing an adequate inflammatory
response to pneumococcal CNS infection [48]. However,
superoxide, as well as other ROS, can also cause damage
to the brain by oxidizing nucleic acids, proteins and mem-
brane lipids.
During BM, hypoxanthine accumulates as a consequence
of ATP breakdown [49]. Xanthine oxireductase converts
hypoxanthine to xanthine and then to urate. This enzyme
may be converted from the xanthine dehydrogenase form
(Table 1, #58) to the xanthine oxidase form. The later uses
molecular oxygen as electron acceptor, thereby generating
superoxide and other ROS [50]. In advanced BM, urate
accumulates in the CSF and CX and the activity of xan-
thine oxireductase, mainly in its innocuous dehydroge-
nase form, increases [51]. The oxidative damage
associated with BM is inhibited by treatment with antioxi-
dants reducing cerebral ischemic damage and preventing
cerebral blood flow reduction [47,52]. Among the group
of endogenous antioxidant enzymes, which includes
superoxide dismutase (SOD), catalase and glutathione
peroxidase (Table 1, #62, #63), the last-named was the
only one we found to be continuously upregulated in the
early and late phases of acute BM. SOD mitochondrial
precursor was transiently upregulated in early acute BM in
the CX and HC; catalase and extracellular SOD (copper-
zinc SOD) were transiently downregulated in the early
acute BM only in the HC (data not shown). Glutathione
peroxidase reduces lipid hydroperoxide substrates to the
corresponding hydroxy fatty acid, and then is regenerated
to its native form by reduced glutathione. Glutathione S-
transferases (GSTs) represent a major group of detoxifica-
tion enzymes, which includes the membrane-bound
isoenzyme microsomal GST 1 (Table 1, #59, #60). GSTs
detoxify some of the toxic carbonyl-, peroxide- and epox-
ide-containing metabolites produced within the cell by
oxidative stress. GSTs are strongly induced by ROS [53].
The expression kinetics of the above-mentioned redox
homeostasis-related genes indicate that SOD and catalase
are early mediators of the antioxidant defence mecha-
nisms while the glutathione system is activated mainly in
the late phase of acute BM.
Besides its function in catalyzing the first and rate-limiting
step in heme degradation, heme-oxygenase-1 (HO-1;
Table 1, #59, #60) may also play a protective role against
oxidant-mediated injury. HO-1 is highly induced by some
key mediators of the host response to BM such as inflam-
matory cytokines and prostaglandins [54].
Ischemia
In advanced BM, cerebral blood flow is reduced causing
cerebral ischemic injury and neuronal death [55,56]. We
found two main proteins that play a role in controlling
blood flow to be differentially regulated in this study. Tro-
pomyosin (Table 1, #52), regulates the contraction of vas-
cular muscle cells [57]. Tropoelastin (Table 1, #48),
induce an endothelium-dependent vasorelaxation medi-
ated by the elastin/laminin receptor and by endothelial
NO production [58]. Upregulation of tropomyosin in the
CX and downregulation of tropoelastin in the HC may
account for the loss of vascular autoregulation and reduc-
tion in cerebral blood flow and ischemia in the late phase
of acute BM.
Upregulation of glial fibrillary acidic protein (GFAP; Table
1, #24) is a marker of astrocyte activation. One aspect of
astrocyte activation may be neuroprotection against exci-
totoxicity by uptake of excess glutamate and conversion to
glutamine via the enzyme glutamine synthase. Our results
indicate that astrocytes are already highly activated in the
early acute BM and their activation persists well into the
late phase of acute BM.BMC Biology 2006, 4:15 http://www.biomedcentral.com/1741-7007/4/15
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CX3CR1 (Table 1, #25), a G-protein coupled chemokine
receptor, is expressed in the activated microglia cells of
ischemic brain. In ischemia, the neuronally expressed
chemokine fractalkine may participate in the activation
and chemoattraction of microglia into the injured area
acting through CX3CR1 [59]. Allograft inflammatory fac-
tor-1 (AIF-1; Table 1, #26–#27) is a putative calcium bind-
ing peptide also associated with microglia activation in
the brain [60]. Our data on the transcription kinetics of
CX3CR1 and AIF-1 indicate that microglia activation
might reach maximal levels during the late phase of acute
BM.
Metabolites of the kynurenine pathway, the metabolic
pathway leading from tryptophan to NAD, have been
implicated in several neuropathological conditions such
as epilepsy, neurodegenerative disorders, global ischemia
and neuronal death in the course of acute or chronic
inflammatory diseases. The increased transcription of
kynurenine 3-hydroxylase (Table 1, #65) in early and late
acute BM can lead to the accumulation in the CX and HC
of the potentially neurotoxic compounds 3-OH-kynure-
nine and quinolinic acid (QUIN), which may cause neu-
ronal death of either the excitotoxic or apoptotic type. 3-
OH-kynurenine is readily oxidized and gives rise to highly
reactive hydroxyl radicals, which are known mediators of
cell death. QUIN is an agonist of a subset of N-methyl-D-
aspartate (NMDA) glutamate receptors. In contrast, when
kynurenine, the substrate of the enzyme kynurenine 3-
hydroxylase is available, kynurenic acid (KYNA) concen-
trations in CSF and in brain extracellular spaces increase
significantly [61-64]. KYNA is an antagonist of the NMDA
receptor and acts neuroprotectively (reviewed in [65]).
Accordingly, adjunctive KYNA reduces neuronal injury in
the CX and in the HC of infant rats with group B strepto-
coccal meningitis [66].
Cell death/survival
In pneumococcal meningitis, apoptosis has been reported
as a major mechanism of damage to the hippocampus
leading to learning and memory impairments following
the disease [2,31]. In the infant rat, neuronal apoptosis
caused by experimental pneumococcal meningitis was
caspase-3 dependent and localized to the granule cell
layer of the hippocampal dentate gyrus corresponding to
immature neurons and/or neuronal progenitor cells [30].
Some archetypal pro-apoptotic genes, such as those
encoding caspase-1 [67] and peripheral-type benzodi-
azepine receptor [68], were upregulated in the CX and in
the HC (Table 1, #72, #74). Importantly, most genes
included in the cell death/survival group that were contin-
uously upregulated in early and late phases of acute BM
only in the HC, e.g. those encoding cyclophilin C [69],
apoptosis-inducing factor (AIF) [70], h-rev107 [71] and
metastasis suppressor homolog [72,73] (Table 1, #66–
#69)], are pro-apoptotic, and those continuously upregu-
lated only in the CX. e.g. Tyms (thymidilate synthase) [74]
and  Tep1  (telomerase protein component 1) (Table 1,
#70, #71) [75] are anti-apoptotic.
In the course of BM, the immunoreactivity of the caspase-
3 precursor protein in hippocampal homogenates is
decreased, paralleled by an increasing signal for active cas-
pase-3 from 18 h after infection on [34]. These findings
suggest that caspase-3 activity is mainly regulated at a
post-translational level. Accordingly, transcription of cas-
pase-3 was not differentially regulated in the present
study.
Galectins (Table 1, #75–#78) are a family of carbohy-
drate-binding proteins defined by affinity for beta-galac-
toside and sequence homology of the carbohydrate-
binding motif. Among the members of this family, Galec-
tin-3 is the only one known so far to inhibit apoptosis,
while galectin-9 is pro-apoptotic. Galectin-3 is expressed
in a variety of cell types including activated microglia, sub-
populations of dorsal root ganglia neurons and Schwann
cells after nerve injury (reviewed in [76]). Galectin-9
induces apoptosis in T cell lines and other types of cell
lines via the Ca2+-calpain-caspase 1 pathway [77]. In
human astrocytes, Galectin-9 expression is enhanced by
Il-1-beta [78]. Should the cellular sources and targets of
galectin-3 and -9 be identified in the BM brain, their role
in limiting the inflammatory reaction and/or neuron
death may be clarified.
Growth control/neuroplasticity
The results from this study indicate that besides the mech-
anisms directly driving cell death in the brain during BM,
such as the activation of pro-apoptotic genes, brain injury
is further modulated by mechanisms controlling cell
growth and neuroplasticity.
TGF-beta1 [79] and activin [80] (Table 1, #85, #86) are
both strongly induced in the infant rat brain following
hypoxia-ischemia. In an rabbit model of pneumococcal
meningitis, activin level in the CSF rose 15-fold in 24
hours and correlated positively with CSF protein content,
microglia activation and the number of apoptotic neurons
in the dentate gyrus [81]. According to our data, TGF-
beta1 is upregulated at the transcriptional level while
activin is not. This could be due to the high stringency
threshold we used to define differential gene regulation,
or to the intrinsically low sensitivity of microarrays. Our
results do not exclude the possibility that transcription of
activin is upregulated in the very early disease, before 22
h. Post-transcriptional activation should also be consid-
ered.BMC Biology 2006, 4:15 http://www.biomedcentral.com/1741-7007/4/15
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Neurotrophin-3 (NT-3; Table 1, # 88) is involved in the
survival of neurons and the modulation of the immune
system (reviewed in [82]). The transcriptional downregu-
lation of NT-3 in the late phase of acute BM may account
for the neuron loss in our infant rat model of BM. How-
ever, our results contrast with a previous report of elevated
CSF levels of NT-3 in patients with BM [83].
Granulins (Table 1, #89–#90), also called epithelins, are
peptides with growth factor modulatory effects on a vari-
ety of cells. They are expressed in a number of epithelia
and in specific neurons in the brain, including pyramidal
cells of the HC and defined neurons in the CX. Progranu-
lin plays important roles in immunological and neuronal
function [84]. Progranulin activates the PI3K signalling
cascade, among others, and increases expression of cyclins
B and D (Table 1, #81, #82). Intact progranulin is anti-
inflammatory through the inhibition of TNF, while the
proteolytic peptides generated by elastase may stimulate
the production of inflammatory cytokines such as IL-18
[2]. 42A (Table 1, #90) is an S100-like protein of which
the mRNA is induced in PC12 cells by nerve growth factor.
S100 beta proteins stimulate neurite extension and neu-
ron survival [85].
Glycine is a major inhibitory transmitter in some regions
of the brain, including the HC, and its accumulation in
the brain and CSF has been reported in animal models
and in patients with BM [86,87]. On the one hand, excess
of glycine can be excitotoxic by acting as an agonist of
NMDA receptors. On the other hand, activation of iono-
tropic glycine receptors increases chloride conductance,
hyperpolarizes the membrane and reduces neuronal excit-
ability (reviewed in [88]). The downregulation of the gly-
cine receptor subunit alpha-1 in the HC (Table 1, #93)
may result in exacerbation of excitotoxicity.
Miscellaneous
This group included a variety of genes that could not be
included in any of the functional groups disclosed by the
literature profiling approach. Within this group, heat
shock protein Hsp27, proteasome subunits beta types 8
and 9 and proteasome activator complex subunits 1 and 2
were continuously upregulated (Table 1 #96, #98–#102).
Heat shock proteins (HSP) are potent regulators of apop-
tosis [89]. Hsp27 is an ATP-independent chaperone that
confers protection against apoptosis through various
mechanisms, including direct interaction with cyto-
chrome c after its release from mitochondria [90], or Akt
activation [91]. Hsp27 also enhances the degradation of
ubiquitinated proteins by the 26S proteasome in response
to stress-inducing stimuli such as TNF-alpha [92]. The
ubiquitin-proteasome pathway is involved in the activa-
tion of NF-κB by enhancing degradation of its main inhib-
itor I-kappaBalpha. This function of Hsp27 would
account for its antiapoptotic properties through the
enhancement of NF-κB activity [93].
Conclusion
High throughput analysis of gene expression in the CX
and in the HC during the early and late phases of acute
pneumococcal meningitis revealed functional groups of
differentially regulated genes. The rat U34A chip contains
only a subset of the entire rat genome, in comparison to
current U230 versions that contain essentially whole
genomes. Thus, the array used herein covers merely one
third of the putative 30000 genes of the rat genome and
therefore only a fragmented description of the rat tran-
scriptome is at hand. The probesets on U34A represent the
most highly annotated and well characterized genes
known at the time it was produced and the selection may
be biased towards genes that are already known to be
important in critical pathophysiological processes. Never-
theless the selection of genes represented on the rat U34A
chip is not biased towards a specific process and covers a
wide range of the cellular transcriptional network. Our
results are validated by the finding that most genes previ-
ously reported in BM are differentially regulated herein.
Furthermore, evidence was obtained from the literature
analysis to implicate a number of genes not previously
known to play a role in the pathophysiology of BM. These
genes represent 80% (62/82) of all those that were differ-
entially regulated continuously in early and late phases of
acute BM. In general, factors capable of promoting inflam-
mation are continuously upregulated in the HC, but not
in the CX, from early to late acute BM. This confluence of
pro-inflammatory stimuli may account for a stronger and
longer local response in the HC than in the CX; this phe-
nomenon may favor apoptosis rather than necrosis as the
predominant mechanism of cell death in hippocampal
neurons. The data presented herein may provide a road
map for further investigations into the pathophysiology
of pneumococcal meningitis and may help to identify
potential targets for adjuvant therapy of this disease.
Methods
Model of meningitis
An established infant rat model of pneumococcal menin-
gitis was used as described previously [5]. The animal
studies were approved by the Animal Care and Experi-
mentation Committee of the Canton of Bern, Switzer-
land, and followed National Institutes of Health
guidelines for the performance of animal experiments.
Briefly, nursing Sprague-Dawley rats with their dams were
purchased (RCC Biotechnology & Animal Breeding, Fül-
linsdorf, Switzerland), and infected (n = 10) on postnatal
day 11 by intracisternal injection with 10 μl of saline con-
taining log10 6.4 cfu/ml of Streptococcus pneumoniae (sero-
group 3). The infecting organism was initially isolatedBMC Biology 2006, 4:15 http://www.biomedcentral.com/1741-7007/4/15
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from a patient with pneumococcal meningitis and has
undergone multiple passages through infant rats in the
course of experimental studies [14,94]. Mock-infected
control animals (n = 5) were injected with 10 μl of saline.
Eighteen hours after infection, the animals were weighed
and the severity of the disease was scored using the follow-
ing scale: 1 = coma; 2 = does not stand upright; 3 = stands
upright within 30 seconds; 4 = minimal ambulatory activ-
ity, stands upright in less than 5 seconds; and 5 = normal
[94]. Cerebrospinal fluid (CSF) was obtained by puncture
of the cisterna magna and used for quantitative bacterial
titers. Antibiotic treatment with ceftriaxone (100 mg/kg,
subcutaneously q12 h; Roche Pharma, Reinach, Switzer-
land) was started. Animals were sacrificed with an over-
dose of pentobarbital (100 mg/kg, intraperitoneally) at 22
h for the mock-infected control group (n = 5) and for the
group representing the early phase of acute BM (n = 5).
Animals representing the late phase of acute BM (n = 5)
were sacrificed at 44 h after infection.
Tissue processing
Animals were perfused via the left cardiac ventricle with
30 ml of ice-cold, RNase-free phosphate buffered saline
(PBS) followed by 30 ml of 50% RNAlater® (Ambion
Europe Ltd., Huntingdon, UK) in ice-cold, RNase-free
PBS. Immediately afterwards, the meninges were removed
from the brains. The hippocampi and the cortical hemi-
spheres were dissected and stored separately in 150 μl of
RNAlater® at 4°C until isolation of RNA [5].
RNA processing and hybridization
Tissue samples from CX and HC of each animal were
processed and analyzed separately. Total RNA was
extracted from brain samples using RNAzol (Tel-Test Inc.,
Friendswood, TX) and a commercially available kit (Bio
101, Carlsbad, CA) [5]. Total RNA was purified with RNe-
asy columns (Qiagen, Basel, Switzerland) before quantifi-
cation and assessment of ribosomal RNA integrity on
agarose gels. Double-stranded cDNAs were synthesized
from 20 μg of total RNA using an oligo dT-T7 promoter
primer (Roche Molecular Biochemicals, Mannheim, Ger-
many). The cDNAs obtained were used as templates for in
vitro  transcription using the Megascript kit purchased
from Ambion (Austin, TX) and biotinylated nucleotides
(Bio-11-CTP and Bio-16-UTP) provided by Roche Molec-
ular Biochemicals. Fragmented in vitro transcripts (cRNAs)
were hybridized overnight on to commercially available
rat microarrays containing 8799 rat specific probe sets
(GeneChip® Rat Genome U34A, Affymetrix, Santa Clara,
CA). The hybridized samples were stained with streptavi-
din-R phycoerythrin (SAPE, Molecular Probes Inc.,
Eugene, OR) and the signal amplified using a biotinylated
goat anti-streptavidin antibody (Vector Laboratories, Bur-
lingame, CA) followed by a final staining with SAPE.
Washing, staining and amplification were carried out in a
fluidics station provided by Affymetrix. Microarrays were
scanned in an Affymetrix GeneArray scanner (gain setting:
18,000). The image files obtained were analyzed using
Microarray Suite 3.0 software (Affymetrix). The distribu-
tion of the samples on the microarrays was n = 4 for cortex
and n = 5 for hippocampus in the mock-infected control
group (n = 9); n = 5 for cortex and n = 5 for hippocampus
in the group that was sacrificed at 22 hours after infection,
in the early phase of acute BM (n = 10); and n = 5 for cor-
tex and n = 5 for hippocampus in the animals that were
sacrificed at 44 h after infection (n = 10), in the late phase
of acute BM. Samples were not pooled and explants from
CX and HC of each animal (n = 15) were processed and
hybridized separately yielding a total of 29 independent
readings.
Raw data analysis
The Affymetrix® .CEL files containing the unprocessed raw
data of each rgu34a Array used in this study can be down-
loaded from [95].
Raw data analyses were carried out using RACE-A version2
software (F. Hoffmann – La Roche, Basel, Switzerland)
[96]. For quantification of relative transcript abundance,
the average difference value (Avg Diff) was used. All chips
were normalized against the mean of the total sums of Avg
Diff values across all 29 chips. We selected for further
analysis only those probe sets with a reproducible change
factor of their Avg Diff ≥ 1.5 (p ≤ 0.05) in the CX and/or
HC when at least two of the three defined conditions were
compared (i.e. early and late phases of acute BM, and
mock-infected controls).
Literature profiling
We implemented the literature-profiling algorithm of
Chaussabel and Sher [9] in a Perl program (see Additional
file 1: Our implementation of the literature profiling algo-
rithm of Chaussabel and Sher). The output of our pro-
gram can be described as a term-by-gene matrix of term-
frequencies. The matrix was used to group genes by hier-
archical clustering based on their shared vocabulary using
the software packages Cluster and Tree View [97]. We
applied the average linkage clustering algorithm to the
two axes of the matrix (genes and terms) and the similar-
ity metric method was the centered correlation. The
results are visualized as a clustergram representing genes
clustered according to their patterns of term occurrences
(Figure 1).
Self-organizing map (SOM)
SOM as implemented in the software GENECLUSTER 1.0
(MIT, Cambridge, MA) was used to group the 598 Affyme-
trix probe sets into clusters on the basis of similar expres-
sion kinetics over the three defined conditions for the CX
and the HC independently. Avg diffs were converted toBMC Biology 2006, 4:15 http://www.biomedcentral.com/1741-7007/4/15
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"zero" when no significant change was observed accord-
ing to the criteria defined above in the section "Raw data
analysis". The SOM algorithm reduces the dimensions of
data through the use of self-organizing neural networks.
GENECLUSTER 1.0 reduces dimensions by producing a
bi-dimensional map that plots similar data items grouped
together [10].
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